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Abstract
Background: Medication use in pregnancy walks a fine line between safety of the mother and
adverse effects in the developing fetus. Medications are prescribed to either help the mother
maintain mental stability or they are discontinued out of fear of fetal harm. Many providers hope
that the shift in hormones during pregnancy will fulfill the medications requirement in the nonpregnant state but this is not always the case. Is a discontinuation in medications upon a positive
pregnancy test warranted?
Purpose: To determine if antipsychotics, mood stabilizers, and antidepressants should be
continued or discontinued during pregnancy or if they negatively impact the fetus/neonate
development, maternal wellbeing, and/or maternal-fetal interactions.
Results: Continuation of medications has a high correlation with adverse fetal effects as well as
adverse maternal metabolic syndromes. Discontinuation of medications has a high correlation
with maternal relapse and adverse fetal effects due to maternal illness. More research is needed
to be able to fully assess the safety of antidepressants, antipsychotics and mood stabilizers in
pregnancy.
Conclusion: Midwifery care is helpful to patients in understanding all their options while taking
medications in the antidepressant, antipsychotic, and mood stabilizing families during
pregnancy. Each situation and patient need to be treated individually and care needs to be patient
based. Midwives must educate patients and help them to make an informed choice as to
continuing or discontinuing psychotropic medications during pregnancy.
Implications for Research and Practice: Careful consideration needs to be given based on each
diagnosis and situation. Some situations may call for a discontinuation of medications while
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others indicate continuation for best outcomes. Education and current research is more important
than fear of liability and current trends.
Keywords: antipsychotics, antidepressants, mood stabilizers, pregnancy, maternal effects, fetal
effects, neonatal effects, adverse effects, drug use, fetal outcomes, maternal outcomes, mental
illness, medications
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Chapter I: Introduction
Pregnancy can be one of the most meaningful and life fulfilling experiences for a woman
and family when they are ready for a child and even sometimes when they are not. However,
pregnancy and fetal development can also be an overwhelming experience even for a healthy,
mentally stable woman. For a woman with mental illness, the experience can be much more
complicated. Unfortunately the onset of mental illness most commonly occurs in women ages
20-30 (National Alliance of Mental Illness, 2015), which coincides with a woman’s child bearing
and child rearing years. With the added complication of mental illness and the high risk
medications that women may be required to take daily, pregnancy can be an overwhelming,
terrifying, and unpredictable experience.
Many women with mental illness do not understand the medications that they are
required to take each day nor do they understand the possible effects that these medications
could have on their developing fetus. Individuals with mental illness such as bipolar disorder,
schizophrenia (paranoid and nonspecific), and personality disorders, are required to take
medications daily to actively decrease their symptoms and reduce the risk of a threat of harm to
themselves or others within the community. However the medications that are most commonly
prescribed to effectively treat these disorders by keeping the patient symptoms under control
have the ability to negatively affect the developing fetus while benefitting the mother’s mental
health status. In past decades physicians have routinely taken pregnant women off of
antipsychotics, mood stabilizers, and even some antidepressant medications at the woman’s first
perinatal visit hoping that pregnancy hormones would take over and stabilize the woman during
pregnancy, thereby protecting the fetus from adverse medications side effects (Galbally, Snellen,
Walker, & Permezel, 2010). Unfortunately, relying on pregnancy hormones alone does not
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always keep the mother’s symptoms at bay, leading some women to find themselves in a
destructive, decompensating spiral and the medical community wondering: how can we treat
mental illness during pregnancy? And most importantly how do we do this safely? Perinatal care
is primarily focused on keeping mother and baby happy, healthy, and safe. For patients suffering
from mental illness, how can we ensure a continued focus on happiness, health, and safety?
Statement of Purpose
Although the popular assumption by many physicians and midwives is to discontinue
antipsychotics, mood stabilizers, and some forms of antidepressants to prevent fetal harm, there
are no definitive sources to support this approach. On the other hand there are also no definitive
sources to show that it is better to allow women to decompensate causing many more
complications. The purpose of this critical review of the literature is to determine if
antipsychotics, mood stabilizers, and antidepressants should be continued or discontinued during
pregnancy or if they negatively impact the fetus/neonate development, maternal wellbeing,
and/or maternal-fetal interactions.
Need for the Critical Review of the Literature
Use of antipsychotic medication prescriptions are on the rise within the pregnant
population (Vigod, Gomes, Wilton, Taylor, & Ray, 2015). This increase is most notably due to
an increased “use of atypical antipsychotics in the treatment of bipolar and major depressive
disorder” (Vigod et al, 2015, p 1). With this increase that has effects on both mother and the
developing fetus, there is a need to review and understand the evidence surrounding the use of
these medications in pregnancy. Most studies have spent the majority of their focus on older
generation antipsychotic medications, however, many psychologists are now prescribing atypical
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antipsychotics. This change has made previous research less applicable as providers are not
reviewing the risks and teratogenic effects these medications have on a developing fetus and
maternal complications in pregnancy (Petersen, McCrea, Osborn, Evans, Pinfold, Cowen, Gilbert
& Nazareth, 2014). This lack of guidance and education for women of child bearing age is
concerning as many individuals with mental health disorders tend to participate in high risk
behaviors. Such behaviors could include sexual promiscuity, prostitution, or even illegal drug
use making sexuality and contraceptive education a priority. The lack of education by the
psychiatric providers to their patients may be the first gap in care, leaving the bulk of education
to the midwife after pregnancy has occurred. The decision then needs to be that of a mutual one
between the patient and the midwife. Finding the best balance between keeping the mother from
relapse and keeping the fetus healthy is key to overall care when looking at antepartum women
with mental health disorders using antipsychotics, mood stabilizers, and antidepressant
medications.
The midwife’s overall goal is to help healthy low risk women to maintain their health and
mental wellbeing in order to have a healthy pregnancy and raise a healthy baby. Medications
need to be evaluated but not necessarily discontinued or changed. Evaluating the woman for
mental stability and insight into her mental health disorder is an important factor in determining
what steps need to be taken to maintain the patient’s physical and mental wellbeing and ensure
healthy fetal growth and development. Midwives need to be knowledgeable about what adverse
effects antipsychotics, mood stabilizers, and antidepressants can have on fetal growth and
development, but also what negative impacts the discontinuation of these medications could have
on the mother during both antepartum and postpartum period.
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In addition to the knowledge of the midwife and collaboration with the patient, more
research on how antipsychotics, mood stabilizers, and antidepressants impact fetal wellbeing in
humans is needed to be able to accurately determine if and how these medications are negatively
impacting fetal development and maternal-fetal interactions. Or, is mental illness itself a main
contributing factor to pregnancy and fetal complications and development?
Significance to Nurse-Midwifery
Nurse midwives are at the forefront in obstetric and gynecological care of low risk
healthy women; “midwives can offer a cost-effective way of providing safe and excellent
maternity care” (Budin, 2015, p.76). This population includes women with mental illness and
other disorders. Unfortunately, for women many mental illnesses and their symptoms occur in
the mid-to-late 20’s. At this point in a woman’s life they may not fully understand their mental
illness, lacking insight to the situation that presents itself, thus making pregnancy and treatment
of symptoms difficult and trying. Women are going to continue to get pregnant while on
medications to treat schizophrenia, bipolar disorder, and depression. Women are going to
continue to present in clinic with a viable pregnancy and an active prescription of antipsychotics,
mood stabilizers, and antidepressants. It is ultimately up to the midwife to refer to the
psychiatrist, reevaluate medications, or adjust antepartum cares accordingly.
An example includes the medication, lithium which is used to treat mania and bipolar
disorder. According to James et al. (2009), lithium “increases the risk of the cardiac defect
Ebstein’s anomaly; approximately one in 500 births are affected, a 40-fold increase over the
background rate” (p. 137). Midwives should be just as knowledgeable about medications for
mental health as physicians because mental health patients are not classified as high risk and fall
into the population of clients that midwives treat. Midwives are fully capable of caring for
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pregnant women with a mental health diagnosis. Furthermore, midwives caring for women
before pregnancy should be “taking steps to warn patients of the teratogenic risks, prescribing
folate when appropriate, and discussing contraception” (James et al., 2009, p. 138) to ensure
awareness in this patient population. Mental illness is and will continue to be a complication of
pregnancy. Understanding when it is best to discontinue medications or continue medication in
pregnant women is key to maintaining effective patient care. Midwives must weigh the benefits
and risks for both mother and child when looking at negative fetal effects, negative maternal
effects, and negative effects after birth.
Theoretical Framework
The theoretical framework that was chosen for this critical review of the literature is the
Theory of Human Caring/Caring Science by Jean Watson. This theory looks at how effective
antepartum care medically, psychologically, and fetal surveillance can prevent complications in
the fetus and developing child after birth in regards to physical and mental development. Jean
Watson’s Theory of Human Caring/Caring Science shows how adequate care of patients can
help both the patient and unborn child prosper in growth and development.
Jean Watson’s Theory of Human Caring/Caring Science is based on the love and moral
values of the healthcare professional showing that one must go past themselves – giving above
and beyond to ensure the best possible outcome for their patient (Wagner, 2010). This applies
mainly to the prescriber. When a prescriber is recommending antipsychotics/mood
stabilizers/antidepressants to women of child bearing age they need to ensure that adverse effects
to fetal development are reviewed as well as a full understanding of pregnancy prevention and
contraceptive use. The Theory of Human Caring/Caring Science has seven main components that
make up the theory overall, including 1: moral commitment to protect and enhance human
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dignity, 2: respect/love for the person, 3: caring consciousness of the situation, 4: heart centered
care of mind body and spirit, 5: inner harmony, 6: caring conscious intention, and 7: authentic
presence (Wagner, 2010, p. 1). Once pregnancy has occurred the mother needs to be adequately
informed of all her options and she needs to understand the situation in full (component one).
Once all decisions have been made, the nurse midwife is to continue to support and encourage
the mother to her full potential (component two and four). Many mental health patients lack the
insight into their illness and may not understand what is required for child bearing and rearing.
Ensuring the mental health diagnosis is in the forefront of a patient’s antepartum care is
important when making decisions to continue or discontinue medications that could negatively
impact the developing fetus (component three, four, and five). Decisions such as these need to be
made with the patient’s input and understanding of both the benefits and risks of discontinuing or
continuing a medication regime that includes antipsychotics, mood stabilizers and or
antidepressants (components five, six and seven).
Summary
As the use of atypical antipsychotics, mood stabilizing, and antidepressant medication
increases, further investigation is required to ensure the best possible outcome for the mother and
developing fetus. Preventing maternal decompensation and ensuring proper fetal development is
the ultimate objective of both the midwife and all other professionals involved. Midwives must
be knowledgeable regarding risks and benefits to both the mother’s metal health and fetal
wellbeing when faced with the decision to either discontinue or continue high risk medications
such as antipsychotics, mood stabilizers, and antidepressants.
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Chapter II: Methods
This chapter will address the critical review of the literature and the methods used in the
review process. Literature includes studies related to antipsychotics, mood stabilizers, and
antidepressant use in pregnancy, adverse effects on birth outcomes with medication use, and
relapse in pregnancy after discontinuation of medications during pregnancy were all included.
Criteria for exclusion or inclusion of research will be considered. The studies that were used will
be reviewed and lastly, the evaluation process will be explained.
Search Strategies
The purpose of this critical review of the literature was to understand the maternal and
neonatal complications in relation to the continuation or discontinuation of maternal
antipsychotic, mood stabilizer, and or antidepressant use during pregnancy. Research was found
for this topic using search engine databases including the Cumulative Index to Nursing and
Allied Health Literature (CINAHL), Elton B Stephens Company (EBSCO) and The National
Center for Biotechnology Information (NCBI) that led to PubMed.
The initial search through CINAHL used key words such as “antipsychotics” and
“pregnancy” and “antipsychotics” and “fetal development.” The results showed 52 items
published between the years of 2000 and 2015. The second search through CINAHL used keys
words such as “mood stabilizers” and “pregnancy.” This search showed 23 items published
between the years of 2000 and 2013. The final search on CINAHL used key terms such as
“antidepressants” and “pregnancy” along with “antidepressants” and “fetal development.” This
search showed 270 items between the years of 1995 and 2015. The next search engine database
that was used was EBSCO. Key terms used to limit the number of information sources were
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terms such as “Maternal Antipsychotic Use” and “Pregnancy”; “Maternal Antipsychotic Use”
and “Fetal Development”; “Maternal Mental Illness” and “Fetal Development”; “Maternal
Mental Illness” and “Pregnancy”. These searches revealed a total of 513 items between the years
of 1975 and 2015. The final search engine database that was used was NCBI which led to
PubMed database. Key words such as “Mental Health” and “Pregnancy”; “Antidepressants” and
“Pregnancy”; “Mood Stabilizers” and “Pregnancy”; “Schizophrenia” and “Pregnancy”; and
“Schizophrenia” and “Fetal Development.” These searches revealed a total of 9,609 items
between the years of 1959 and 2015 overall. This time frame was then limited to more current
research for years 2000-2015.
After reviewing and searching the literature found on CINAHL, EBSCO, and PubMed
subject terms such as “Maternal Mental Health”, “Fetal Development”, “Pregnancy”,
“Antipsychotic Use”, “Mood Stabilizers”, “Antidepressants”, and “Schizophrenia Drug
Therapy”, were the main subject terms used to reduce the amount of items by almost half on all
search databases. The search year was also limited to the year 2000 to 2015, greatly reducing
items to a total of 348 items on CINAHL, 349 items in EBSCO and 5,403 items in PubMed. In
addition to the research search engine databases that were used, the reference lists within the
research items analyzed generated additional items for review. Research was then limited to
research that focused on maternal and fetal outcomes after exposure or continuation of
medications such as antidepressants, antipsychotics and mood stabilizers. Research that focused
on maternal conditions treated with these medication for other reasons besides mental health
complications were excluded thus limiting the research found. This criteria limited search within
the databases to 98 items on CINAHL, 116 items in EBSCO and 124 items in PubMed.
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Exclusion or Inclusion of Research
When reviewing the literature, many articles did not pertain to the purpose of this
critical review nor to the critical review question. Articles that referred to epileptic medications
and fetal complications were excluded as this did not pertain to the review question. Other items
that were excluded were items that referred to only maternal complications as they did not
answer the review question such as comorbidities that need additional medical treatments.
Lastly, research that was not of relevant timing was excluded in the matrices as it is no longer
applicable to the integrity of this critical review. Items that were included in the matrices for this
critical review of the literature are non-experimental, meta-analysis, non-randomized controlled,
quantitative, and qualitative research studies that were categorized in the high or good quality of
research according to the John Hopkins Level and Quality review (Dearholt, & Dang, 2009).
Studies that considered maternal and perinatal outcomes with maternal antipsychotic use,
antipsychotic use in pregnancy and safety, SSRI antidepressant use and fetal effects, mood
stabilizers and the teratogenic effects on fetal development and maternal wellbeing, antenatal
monitoring for bipolar and schizophrenic women and relapse in mothers with antidepressant or
antipsychotic discontinuation during pregnancy were included in the final matrix as seen in
chapter 3.
Studies Selected
The initial search yielded 6,100 studies and the final search after the exclusion criteria
was implemented yielded 388 studies that related to maternal antipsychotic or mood stabilizer or
antidepressant use in pregnancy, maternal antipsychotic or mood stabilizer or antidepressant use
and fetal development, mental illness and pregnancy or fetal development, and discontinuation of
schizophrenia medications during pregnancy. These studies were reviewed and sorted by
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relevance and current data. Studies were sorted in reference to the type of research, quality and
expert opinion, the John Hopkins level of research and lastly how the study pertained to the
review subject question thus obtaining the final 25 studies used in this capstone. Each study was
assessed for its relevance to the review question: to determine maternal and neonatal
complications in relation to the continuation or discontinuation of maternal antipsychotic, mood
stabilizer, and/or antidepressant medication use during pregnancy. Of the 25 items that were
included for the final review of the literature, fifteen were non-experimental, four were
experimental, and six were grounded theory.
The 25 final items that were chosen for this critical review of the literature are organized
by matrix in chapter three. The matrices are organized by headings which include: citation,
sample, purpose, design, measurement, result/conclusion, recommendations and John Hopkins
level and quality. Each item was carefully chosen and appropriately organized to ensure the
critical literature review could be effectively obtained.
Evaluating the Research
In order to accurately evaluate the research used in this critical review of the literature,
the Johns Hopkins Nursing Evidence-Based Practice: Model and Guidelines (2012) were used.
With this model, research evidence was graded by both quality and level. According to the Johns
Hopkins Nursing Evidence-Based Practice quality and levels, quality is categorized by high,
good and low/poor.
High quality is defined as research that has “consistent results, sufficient sample size,
adequate control, and definitive conclusions; consistent recommendations based on extensive
literature review that includes thoughtful reference to scientific evidence” (Dearholt & Dang,
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2012, p. 108). Good quality is defined as “reasonably consistent results, sufficient sample size,
some control, and fairly definitive conclusions; reasonably consistent recommendations based on
fairly comprehensive literature review that includes some reference to scientific evidence”
(Dearholt & Dang, 2012, p. 108). Low or poor quality is defined as “little evidence with
inconsistent results, insufficient sample size, and conclusions cannot be drawn” (Dearholt &
Dang, 2012, p. 108). According to Johns Hopkins Nursing Evidence-Based Practice the strength
is given a rating determined by levels.
The level of research evidence is broken down into three levels (I, II, III). Level I is
“Evidence obtained from an experimental study, randomized controlled trial (RCT), or
systematic review of RCTs, with or without meta-analysis” (Dearholt & Dang, 2012, p. 108).
Level II is “evidence obtained from a quasi-experimental study or systematic reviews of a
combination of RCTs and quasi-experimental studies, or quasi-experimental studies only, with or
without meta-analysis” (Deerholt & Dang, 2012, p. 108). And lastly Level III is defined as
“evidence obtained from a quantitative non-experimental study; systematic review of a
combination of RCTs, quasi-experimental, and non-experimental studies, or non-experimental
studies only with or without meta-analysis; or qualitative study or systematic review of
qualitative studies, with or without a meta-synthesis” (Deerholt & Dang, 2012, p. 108).
The evidence that was used for this critical review of the literature was based upon the
purpose of the evidence, the data collection method, the evidence sample size, the design of the
study, and the quality of evidence based on the John Hopkins Nursing Evidence-Based Practice
quality and level. They evidence in the matrices hold 14 items of good quality and 11 items of
high quality. Evidence of low or poor quality was excluded from the critical review of the
literature.
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Summary
The effects of antipsychotics, mood stabilizers, and antidepressants on fetal development
and maternal wellbeing are not fully understood. It is difficult to understand the effects of
medication use in pregnant women as many times this can be unethical and complicated research
to complete. The 25 studies used for this critical review of the literature in the final matrix focus
on understanding and determining the best recommendations from both
obstetrician/gynecological, midwifery and psychiatrists’ point of view. This chapter reviewed
evaluation and search strategies that were used to determine the most accurate and up to date
information for this critical review of the literature.
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Chapter III: Literature Review and Analysis
This chapter illustrates a review and analysis of the literature related to determining
maternal and neonatal complications in relation to the continuation or discontinuation of
maternal antipsychotic, mood stabilizer, and or antidepressant medication use during pregnancy.
Mental illness in child bearing age is very common and an ongoing concern with psychiatrists,
obstetricians, and gynecological professions. Determining the best treatment for the most optimal
outcome for the mother and fetus and /or infant is the ultimate goal in mental illness and
pregnancy.
Matrix Results
For this critical review of the literature, 25 pieces of evidence in the form of research
were used. The evidence was organized via matrix. The form of maternal and/or neonatal
complications in relation to the continuation or discontinuation of maternal antipsychotic, mood
stabilizer, and/or antidepressant medication use during pregnancy and its evidence were included
in this review. The Matrix shows information that was deemed beneficial to answer the research
question. The research purpose is: to determine if antipsychotics, mood stabilizers, and
antidepressants should be continued or discontinued during pregnancy or if they negatively
impact the fetus/neonate development, maternal wellbeing, and/or maternal-fetal interactions.
Below the information is summarized based on maternal and fetal effects with maternal
continuation or discontinuation of the medications chosen.
Maternal Effects
The research found that with continuation of antipsychotic medications during any stage
of pregnancy it put mothers at an increased risk of roughly 50% to obtain gestational diabetes
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(Boden & et al., 2012). It was also shown that continuation of antipsychotics put mothers at a
significantly higher increase for instrument vaginal delivery and cesarean sections (Sadowski &
et al., 2013). Antipsychotic use in pregnancy was also greatly linked to higher incidence of
maternal hypertensive disorders, preterm deliveries, placental abruption, induction of labor, and
readmission to the hospital for medical purposes after delivery (Vigod & et al., 2015). The only
benefit to discontinuing medications during pregnancy is that the teratogenic risk to the fetus is
avoided. There were no other benefits for the mother if medications were discontinued during
pregnancy. Multiple studies (Hanley & et al., 2014, Kulkarni & et al., 2008 and Galbally & et al.,
2010) showed that maternal discontinuation of antipsychotics was not proven to be safe as
mothers were at higher risk for decompensation of mental health and a relapse of symptoms
would occur. Mothers had a very significant incidence of readmission to the hospital for
psychiatric decompensation in about 12 months after delivery; it is unclear when mental health
symptoms began to reappear in these cases (Kulkarni & et al., 2014).
Mothers that continued to use mood stabilizers had no significant complications in
pregnancy in the evidence for this critical review. Mothers with bipolar disorder, regardless of
medication continuation or discontinuation showed higher rates of preterm delivery, cesarean
section instrumental vaginal delivery and induction (Boden & Et al., 2012). However mothers
that discontinued medication for mood stabilization had a very high risk of maternal
decompensation or deterioration in mental stability resulting in the lack of ability to care for
child after birth (Galbally, Roberts, & Buist, 2010).
When looking at antidepressant use during pregnancy at any stage the evidence revealed
no significant maternal complications if the medications were continued. However when looking
at discontinuation of medications mother were found to be five times more likely to experience
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mental health decompensation that required hospital admission (Cohen & et al., 2006). Over all
the evidence suggest that with mothers using antipsychotics, mood stabilizers, or antidepressants
the provider should examine each benefit and risk to either continuing or discontinuing the
medications.
Fetal Effects
When examining fetal health and risks, the evidence is much more concerning. When
looking specifically at maternal antipsychotic use during any stage of pregnancy the evidence
shows there is a great increase in risk of fetal harm. Lithium, carbamazepine, and lamotrigine
were shown to cause major structural abnormalities in the fetus such as neural tube, cardiac,
facial, and urogenital defect (Galbally & et al., 2010). Other complications with higher rates of
incidence with fetal exposure to antipsychotics of any classification are floppy infant syndrome,
severe neonatal hypoxemic encephalopathy, neural tube defects, fetal malformation typology and
limb malformation (Gentile, 2010). Neonates had higher rates of admission to the NICU for
respiratory complications and or failure to thrive after exposure in pregnancy (Kulkarni & et al.,
2014). Exposure in pregnancy also showed an increase rate of infants that were large for
gestational age, had withdrawal symptoms such as seizures and even higher rates of
intraventricular hemorrhage (Vigod & et al., 2015). Infants that were followed after birth showed
developmental delay in the social, cognitive, and emotional regard (Wichman, 2009). If mothers
discontinued medications there were no adverse fetal effects.
Mood stabilizing medication showed a significant increased risk for congenital
malformations, infants that are large for gestational age, microcephaly, withdrawal symptoms
such as seizures, hypertonic, hypoglycemia, and an increased risk for Ebstrin anomaly (Galbally,
Roberts & Buist, 2010). Infants also showed increased risk for cardiac defects and severe
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weakness and developmental delays (Kallen & et al., 2013). The evidence showed that with
discontinuation of mood stabilizing medication before pregnancy or after pregnancy has been
confirmed, there was an increased risk of low APGARS, increased fetal hypoglycemia and
infants found to be small for gestational age (Boden & et al., 2012).
For antidepressant use in pregnancy and fetal complications the evidence was conflicting.
Discontinuation of antidepressants during pregnancy was not found in the research. One piece of
evidence discussed continuation and discontinuation of antidepressants in the first trimester of
pregnancy and showed no difference in the major congenital anomalies found in infants born to
women with major depressive disorders or severe anxiety (Ban & et al., 2014). SSRI’s or
selective serotonin reuptake inhibitors (SSRIs) are commonly used in pregnancy; however this
medication family is shown to have adverse fetal effects. SSRIs used in the first trimester of
pregnancy has been linked to a small increased risk for omphalcele, craniosynotosis, congenital
heart defects, conotruncal defects (Louik & et al., 2007). SSRIs have also been linked more
significantly to congenital malformations and cardio vascular defects (Reis & Källén, 2013).
There is no increase in the risk of spontaneous abortion but there is a significant risk in preterm
deliveries, infants that are small for gestation age, intrauterine growth restriction and low
APGAR scores (Ross & et al., 2013). These risks need to be known and risk needs to be assessed
when decisions regarding medication regimen during pregnancy are assessed.
Matrix Synthesis
The 25 research articles used as evidence for this critical review of the literature are
found in the matrix below and are categorized with the following headings: citation, purpose,
sample, design, measurement, results/conclusions, recommendations, Johns Hopkins quality and
level. The research evidence was evaluated by purpose and major findings as well as its
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relevance to the review questions: to determine if antipsychotics, mood stabilizers, and
antidepressants should be continued or discontinued during pregnancy or if they negatively
impact the fetus/neonate development, maternal wellbeing, and/or maternal-fetal interactions.
Research evidence was not included if it was determined to be non-peer reviewed, had a small
sample size, and/or had low or poor quality rating.
Critique of Strengths & Weaknesses
While performing a critical review, strengths and weaknesses of the literature become
apparent. One of the strengths noted in this critical review were large sample sizes. Many
research studies were guided by chart review of mass data bases putting sample size in the one to
ten thousands making the study more reliable and of better quality. Other strengths included
surveying psychiatrists and patients, obtaining personal information from the source such as
doctors and patients in order to better determine factors such as cognitive effects and patient
understanding. Multiple levels of research were used such as qualitative and quantitative, nonexperimental, meta-analysis, randomized, non-randomized, and cohort studies. All research
evidence was of high or good quality based on the Johns Hopkins Nursing Research Evidence
quality guide (2012). Most research evidence was published within the past five years with the
exception of 7 out of 25 studies, however, all research evidence was published within the last ten
years. The determination for inclusion of the research evidence was that of clarity, knowledge,
effectiveness, and accuracy of the information each study provided.
Weaknesses of the studied literature lay mainly in the results and recommendations of
much of the research evidence. Many studies ended with inconclusive results. It is accurate to
state that more research is needed to determine if an antipsychotic, mood stabilizing, or
antidepressant medication is safe during pregnancy or if it will have adverse effects on the
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mother or fetus. Many showed adverse effects on the mother if medications were discontinued or
adverse effects in the fetus if medications were continued. However, many individuals with
mental health disorders also have co-occurring disorders such as health and hygiene neglect,
drug abuse, use of tobacco and/or alcohol, promiscuous behaviors, history of or current sexually
transmitted infections/diseases which could be the cause of poor outcomes and or adverse fetal
effects. These stipulations and co-occurring illnesses were not always covered or addressed in
the research evidence. When medications were discontinued, many women stopped receiving
prenatal care making them hard to follow for this particular research. Also many women stopped
refilling their prescriptions on their own without informing their physician in fear of fetal harm.
This lack of self-care made it hard to continue to follow women making gaps in a starting and
finishing sample sizes when research was completed.
Matrix
Below is the research evidence used for this critical review of the literature to answer the
topic question of determining if antipsychotics, mood stabilizers, and antidepressants should be
continued or discontinued during pregnancy or if they negatively impact the fetus/neonate
development, maternal wellbeing, and/or maternal-fetal interactions as discussed above in the
form of a matrix with 25 articles included.

25

Running Head: MENTAL HEALTH MEDICATION USE IN PREGNANCY
Citation

Purpose

Sample

Design

Measurement

Results/conclusions

Recommendations

Ban L., West J.,
Gibson J. E.,
Fiaschi L., Sokal
R., Doyle, P.,
Hubbard, R.,
Smeeth, L., &
Tata, L. J. (2014)
First trimester
exposure to
anxiolytic and
hypnotic drugs
and the risks of
major congenital
anomalies: a
United Kingdom
populationbased cohort
study. PLOS ONE
9(6): e100996.
doi:10.1371/jour
nal.pone.010099
6

To determine if
anxiolytic and
hypnotic drugs
during the first
trimester of
pregnancy
increase the risk
of major
congenital
anomalies
(MCA).

Singleton live
births from
women ages 1545 y/o between
1999-2010.

Cohort-study
Meta-analysis
Nonexperimental

Data retrieved
from The Health
Improvement
Network (THIN)
(mother and
children’s’ medical
records including,
health, pregnancy,
pharmacology etc.)

Of the total 374,196
live singleton births
2.7% had major
congenital anomalies
19,193 children born
to mothers with
anxiety or depression
but not medicated
and 3,128 children
with first trimester
exposure to
anxiolytic or hypnotic
drugs.

With no evidence of
increased risk of
MCA after exposure
to diazepam,
temazepam,
zopidone or other
anxiolytic or
hypnotic drugs it
would be suggested
that these
medications are
safe during the first
trimester of
pregnancy in
regards to MCA.

495 general
practices were
used from THIN
database to find
the sample
population.
All patients were
anonymizes and
data was
retrieved from
retrieval sites.
Ethical approval
from medical
research ethics
committee.
This excluded
women with
serious mental
illness and
women that
used
antiepileptic
drugs leaving
total of 3,218
children.

Over all looking at
benzodiazepine
and non –
benzodiazepine
used during the
first trimester of
pregnancy (first 12
weeks of
pregnancy)

Major congenital
anomalies (MCA) was
consistent across the
groups.
Mothers with
anxiety/depression
that took
medications had
2.7% MCA
Mothers without
medications with the
same diagnosis had
2.7% rate
No finding suggest
that early antenatal
exposure to
anxiolytic/hypnotic
medication increase
MCA.

Johns Hopkins
Level &
Quality
Quality: good
Level: 2
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Bodén, R.,
Lundgren, M.,
Brandt, L.,
Reutfors, J.,
Andersen, M., &
Kieler, H.
(2012). Risks of
adverse
pregnancy and
birth outcomes
in women treated
or not treated
with mood
stabilisers for
bipolar disorder:
population based
cohort
study. BMJ :
British Medical
Journal, 345,
e7085.
doi:10.1136/bmj.
e7085

Looking at the
outcome
between treating
bipolar women
with mood
stabilizing
medications vs
non medicated
bipolar women
during
pregnancy.

332,137 women
that gave birth
between July 1st
2005 and
December 31st
2009

Random
Non Experimental

All data retrieved
from three Swedish
nationwide
registers
maintained by the
National Board of
Health and
Welfare: Swedish
prescribed drug
register, medical
birth register,
national patient
register.

Women with bipolar
disorder were more
often smokers,
overweight, and more
likely to have
substance abuse
issues over non
bipolar women.

Risks and benefits to
both mother and
fetus must be
weighed when
deciding to treat
women with mood
stabilizers.

Also
understanding
the difference
between
pregnancy, labor,
and child
development
between
medicated
bipolar, nonmedicated
bipolar and nonbipolar women.

320 women had
two bipolar
diagnoses that
were actively
being medically
treated with
mood stabilizers
(lithium,
antipsychotics,
or
anticonvulsants)
during
pregnancy and
554 women who
were untreated.
Both bipolar
groups were
compared to all
other women that
gave birth.

Bipolar women
(treated or untreated)
had higher incidence
of preterm delivery,
C-section delivery,
instrumental delivery,
non-spontaneous
start.
Untreated = low
Apgar scores,
increased fetal
hypoglycemia, small
for gestational age,
Treated = congenital
malformations risk
was higher
Regardless of
treatment women
with bipolar are at an
increased risk for
preterm, instrumental
and/or C-section
deliveries.

Untreated women
showed a variety of
complications
showing that
medications are not
the only cause of
adverse pregnancy,
birth and neonatal
complications

Johns
Hopkins
Level &
Quality
Quality: good
Level: 2
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Boden, R.,
Lundgren, M.,
Brandt, L.,
Reutfore, J., &
Kieler, H. (2012).
Antipsychotics
during
pregnancy:
relation to fetal
and maternal
metabolic
effects. Archives
of General
Psychiatry, 69
(7):715-721.
doi:10.1001/arc
hgenpsychiatry.2
011.1870

To understand
the effects of
maternal use of
antipsychotics
(olanzapine
and/or
clozapine) during
pregnancy on
both gestational
diabetes and
fetal growth

There was a total
of 358,203
singleton births
507 of the
mothers used a
form of
antipsychotics
during
pregnancy 169
used olanzapine
or clozapine
while 338 used a
different
antipsychotic
and they were
compared to the
357,696 mothers
that did not use
antipsychotics
during
pregnancy

Random
Non Experimental
Qualitative

The Swedish
Prescribed Drug
Register, the
Medical Birth
Register, and the
National Patient
Register is where
information was
obtained during
July 2005December 2009 to
obtain
medications,
medical history,
and fetal wellbeing and physical
health.

Both groups
(antipsychotic users
and non-users)
0.4% were stillborn
0.2% neonatal deaths

Antipsychotics such
as olanzapine
and/or clozapine
hold the highest risk
of gestational
diabetes regardless
of maternal
comorbidities.

Then groups of
exposed were
compared to the
non-exposed group

Gestational diabetes
twice as common in
antipsychotic users
Preterm rate of 5% in
non-users and 8% in
users
Large for gestational
age was greater in
olanzapine and
clozapine over any
other antipsychotic
users
Small for gestational
age greater in users
of other
antipsychotics over
non-users.

Proposed to divide
antipsychotics
according to their
adverse effects,
such as the
propensity to cause
weight gain and
metabolic syndrome
when looking at
pregnancy
Further
investigation
needed when
determining drug
safety and
pregnancy.

Johns Hopkins
Level &
Quality
Quality: good
Level: 1
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Cohen, A. S.,
Altshuler, L. L.,
Harlow, B. L.,
Nonacs, R.,
Newport, J.,
Viguera, A. C.,
Suri, R., Burt, V.
K., Hendrick, V.,
Reminick, A. M.,
Loughead, A.,
Vitonis, A. F., &
Stowe, Z. N.
(2006). Relapse
of major
depression
during
pregnancy in
women who
maintain or
discontinue
antidepressant
treatment.
JAMA: Journal of
the American
Medical
Association. 295
(5): 499–
507. doi: 10.100
1/jama.295.5.49
9

To understand
the risk of
relapse in
pregnancy when
women
discontinue their
antidepressant
medications
compared to
women that
continued to use
and follow
treatment.

201 pregnant
women with a
diagnosis of
major depressive
disorder.
Women were
selected from
Perinatal and
Reproductive
Psychiatry
Clinical Research
Program,;
Women’s Mood
Disorders
Research
Program, and
the Women’s
Mental Health
Program,

Longitudinal
Nonexperimental
Non-randomized

Between 1999 2003 assessments
were used to
describe pregnant
women who
elected to
discontinue or
maintained drug
use.
All participants
were informed and
given information
regarding the
study patients gave
consent and selfidentified race and
ethnicity.
Women were
followed only and
not encouraged
either way by the
study to continue
or discontinue
medications.

13 women missed
carried and 5
terminated their
pregnancies. 12
women were lost
due to follow up
before completion of
pregnancy and 8
choose to
discontinue the
study.

The common belief
that pregnancy is a
protective hormonal
states is incorrect
when deal with
underlying mental
illness.

SSRI’s were the most
commonly used
overall
26% of women that
maintained their
medication regimen
relapsed compared
to 86% that
discontinued their
medications
Women that
discontinued their
medications had a 5x
higher relapse rate
61% of women that
discontinued there
medications
restarted
medications after
relapse.

Weighing risks and
benefits is key when
prescribing
medications during
pregnancy, women
need to be
adequately
informed of each
risk and benefit and
relapse of
depression is a risk
just as fetal
malformation.

Johns Hopkins
Level &
Quality
Quality: good
Level: 2
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Evidence-based
review assesses
safety of
antipsychotics
during
pregnancy.
(Cover story).
(2009). Brown
University Child
& Adolescent
Psycho
pharmacology
Update, 11(8), 16.

To determine if
antipsychotic
use during
pregnancy
increase the risk
for birth defects
or other adverse
events

Data analysis
from 1966-2008
that report on
safety of
antipsychotics in
human
pregnancy
Antipsychotic
use in 710
pregnant women
using
antipsychotics.
Most women
were 20-24 years
of age.

Qualitative
Non
experimental

They monitored
the pregnancy to
term or if the
pregnancy was
terminated then
determined if the
fetus had
deformation
psychical and or
mental.

Some antipsychotics
such as
chlorpromazine,
loxapine,
promethazine = no
effects on the fetus
other antipsychotics
such as flupenthixol,
fluphenazine,
haloperidol
perphenazinem
prochlorperazine,
thioridazine and
trifluoperazine =
negative effects on
the fetus

Antipsychotics may
be prescribed
during pregnancy
for various reasons
discontinuing
current
antipsychotics can
seriously negatively
affect the mother
Much assessment of
the risks of nontreatment of the
mother and her
ability to interact
with her newborn,
against a potential
risk to the fetus
much be
considered.

More research is
warranted
Need to prioritize the
maternal
antipsychotic use vs
potential risk to the
newborn.

Johns Hopkins
Level &
Quality
Quality: good
Level 3
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Galbally, M.,
Snellen, M.,
Walker, S., &
Permezel, M.
(2010).
Management of
antipsychotic
and mood
stabilizer
medication in
pregnancy:
recommendatio
ns for antenatal
care. Australian
& New Zealand
Journal Of
Psychiatry, 44(2)
, 99-108.
doi:10.3109/
000486709
03487217

To develop
recommendatio
ns for antenatal
care and
monitoring for
women with
bipolar disorder
and
schizophrenia
who are on
lithium
carbonate,
antipsychotic or
anti-epileptic
medication
during
pregnancy

A review of
published research
review articles and
guidelines for the
psychiatric and
pharmacological
management of
women with
bipolar disorder
and schizophrenia.
Including a
computerized
search of the
electronic
databases
Medline, EMBASE
and PsychInfo for
articles that were
relevant to clinical
assessment of risk
and care in
pregnancy for
schizophrenia,
bipolar, mood
stabilizers and
antipsychotic
medications

Qualitative
grounded
theory

Searches were
also
undertaken of
relevant
guidelines,
reference
books and
bibliographies
of identiﬁed
articles

Increase in teratogenic
risk associated with the
use of sodium valproate,
carbamazepine,
lamotrigine and lithium.
majority of the
structural abnormalities
are central nervous
system anomalies,
particularly neural tube
defects, as well as
cardiac, facial and
urogenital
malformations
postpartum period
comes with a high risk of
maternal relapse regular
assessments and
ongoing monitoring of
the woman’s mental
state through this highrisk period.

Therapeutic drug
monitoring is necessary
for medications such as
lithium,
Carbamazepine,
sodium valproate and
lamotrigine
Stop lithium 24–48 h
prior to delivery or at
delivery, a lithium level
when admitted for
delivery, ensuring
adequate hydration
during labor and
deliver is important
It is important for these
women to avoid sleep
deprivation during the
initial postpartum
period
Infant withdrawal
should be monitored
closely
Discharge planning
should also include the
mother–infant
relationship and,
ideally, support for the
partner or family
involved in supporting
the mother–infant
dyad

Johns
Hopkins
Level &
Quality
Quality:
good
Level: 1
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Galbally, M.,
Roberts, M., &
Buist, A. (2010).
Mood stabilizers in
pregnancy: a
systematic
review. Australian
& New Zealand
Journal Of
Psychiatry, 44(11),
967-977.
doi:10.3109/
00048674.
2010.506637

To undertake a
systematic
review of the
effects of
exposure to
mood stabilizer
medication in
pregnancy,
evaluating
teratogenicity
and other
outcomes for
mother and
child.

A review of
published
research review
articles and
guidelines for the
psychiatric and
pharmacological
management of
women with
bipolar disorder
and
schizophrenia.
Including a
computerized
search of the
electronic
databases
Medline, EMBASE
and PsychInfo for
articles that were
relevant to clinical
assessment of risk
and care in
pregnancy for
schizophrenia,
bipolar, mood
stabilizers and
antipsychotic
medications

Qualitative
grounded
theory

Multiple studies
and case studies
looked at the
medication
duration and
then type of
outcome the
infant had if
living at birth.
Children in he
studies where
then followed
up to 7 years.

All mood stabilizers
were found to be
associated with a risk
of malformation and
perinatal
complications.

More research
needed as most
research they found
related more
epilepsy
All four mood
stabilizers reviewed
may affect fetal
growth and length
of gestation. = fetal
growth surveillance
is recommended
all exposed infants
be observed for
sedation,
withdrawal and
toxicity
Maternal drug levels
should be
monitored in
pregnancy and, in
particular, in the
third trimester
If possible the
patient should make
a conscious decision
with their provider
before actively
trying to get
pregnant

(this looked at
the studies
themselves they
did not do the
actual study)

Johns
Hopkins
Level &
Quality
Quality: good
Level: 1
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Gentile, S.
(2010).
Antipsychotic
therapy during
early and late
pregnancy. A
systematic
review.
Schizophrenia
Bulletin, 36(3): 5
18-544.
doi: 10.1093/sch
bul/sbn107

To determine
the effects of
antipsychotic
medications
during early and
late stages of
pregnancy on
the developing
fetus.

2189 articles
were found
when searching
MEDLINE/PubM
ed, TOXNET,
EMBASE, and
The Cochrane
Library.

Meta- analysis
Nonexperimental
Qualitative

Literature review
Medical literature
information
published in any
language since 1950
was identified using
MEDLINE/PubMed,
TOXNET, EMBASE,
and The Cochrane
Library

Antipsychotics have a
significant increased
risk with birth
defects overall.
With no human data
amisulpride,
ziprasidone, and
sertindole are
considered as
unknown.
Aripiprazole has
unwanted effects on
neonatal cardiac
rhythm so this should
be avoided during
pregnancy.
Clozapine = neonatal
and perinatal
complications
including floppy
infant syndrome and
severe neonatal
hypoxemic
encephalopathy
Olanzapine = SG,
neural tube defects,
Risperidone= fetal
malformation
typology & perinatal
complications
Haloperidol= limb
malformations
All others in study
had minimal risk.

Further information
is needed before
prescribing
antipsychotic
medications during
pregnancy. Each
situation is
different. MD
should weigh pro’s
and con’s prior to
discontinuing or
prescribing
medications

Main focus
diagnosis is
schizophrenic
women pregnant
women.

nd

2 generation
antipsychotics
were
amisulpride,
aripiprazole,
clozapine,
olanzapine,
quetiapine,
sertindole,
ziprasidone,
risperidone
st
1 generation
antipsychotics
were
Butyrophenone,
Diphenylbutylpip
eridine, and
Thioxathene
Derivates.
Haloperidol

Search terms used
were pregnancy,
psychotropic drugs,
(a)typical-firstsecond generation
antipsychotics, and
neuroleptics
Last search updated
on 7/24/08

Johns
Hopkins
Level &
Quality
Quality:
good
Level: 2
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Gentile, S.
(2010). Neuro
developmental
effects of
prenatal
exposure to
psychotropic
medications.
Depression &
Anxiety (10914269), 27(7),
675-686.
doi:10.1002/
da.20706

To determine
the
neurodevelopme
ntal effects on
children that
were exposed to
psychotropic
medications at
any time in the
womb.

Available data
from studies
investigating
developmental
outcome of
children exposed
prenatally to
psychotropics. A
computerized
Medline/PubMed
/
TOXNET/ENBA
SE search
between 1960–
2010
Data were
extracted from
41 articles (38
identified
electronically
and 3 non
electronically

Qualitative
grounded
theory

They used 41
articles total
looking at the
neuro effects of
psychotropics
on the fetus and
developing
infant/child
after exposure.

Antidepressants showed no
significant changes in the
infant.
Lithium showed severe
weakness
Valproate induces
developmental delays
Detrimental effects on
psychomotor and
neurocognitive effects has
been associated with
exposure both throughout
and during late pregnancy
no conclusions can be
drawn about the potential
risk of neurodevelopmental
delay in children whose
mothers need antipsychotic
therapy while pregnant
mood stabilizers are still
very controversial
.

Further investigation
needs to be done as
this looked at only
past research
articles. Many of the
past articles lumped
medication together
and did not take the
time to look at each
medication
specifically.

Johns
Hopkins
Level &
Quality
Quality:
good
Level: 1
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Hanley, G.
E., Mintzes, B.
(2014). Patterns
of psychotropic
medicine use
in pregnancy in
the United
States from 2006
to 2011 among
women with
private
insurance.
BMC Pregnancy
Childbirth,
242(14), 1-12.
doi:
10.1186/14712393-14-242.

To determine
the rate of use of
antipsychotic
medications
during
pregnancy

Overall 343,299
women had live
births from
1/106 to
12/31/11 and of
these women
10.3% were on
one or more
psychotropic
medications
during their
pregnancy

Meta-analysis
Nonexperimental
cohort study

Inpatient and
outpatient
information was
retrieved using the
Truven Health
MarketScan
database
(population base
70 million).

There were 33,995
women on
psychotropic
medications 6
months
preconception then
24,776 continued use
in the first trimester.
15, 883 continued
use in the second
trimester. And
18,161 continued use
in the third trimester.

Psychotropic
medications seem
to be overly
prescribed.
Providers must
weigh the risks and
benefits of
psychotropic
medications on both
the mother and
fetus prior to
starting, changing,
and/ or
discontinuing
medications during
any stage of
pregnancy.
Further
investigation
regarding safety of
medications is still
required.

Johns Hopkins
Level &
Quality
Quality: high
Level: 3

35

MENTAL HEALTH MEDICATION IN PREGNANCY: CONTINUE OR DISCONTINUE
Citation

Purpose

Sample

Design

Measurement

Results/conclusions

Recommendations

James, L., Paton,
C., Lelliott, P.,
Barnes, T., &
Taylor, D.
(2009). Mood
stabilizers and
teratogenicityprescribing
practice and
awareness
amongst
practising
psychiatrists.
Journal Of
Mental
Health, 18(2),
137-143.

To evaluate the
knowledge and
stated practice of
consultant
psychiatrists with
respect to the
prescribing of
these drugs to
women of childbearing age

52 psychiatrists

Qualitative
controlled non
experimental

Semi-structured
interviews with
52 consultant
psychiatrists
Using
questionnaires,
face to face
interviews

Most psychiatrists
did not talk about
contraceptives as
they did not believe
their patients to be
mentally competent.
Across the board
there were no
guidelines followed
for women of
childbearing ages
and monitoring their
current medications
levels.
majority of
psychiatrists report
that they are more
cautious about using
teratogenic mood
stabilizers in women
of child-bearing age,
knowledge of
speciﬁc teratogenic
potential is poor.

It’s encouraging that
so many psychiatrists
claimed to exercise
prudence in
prescribing mood
stabilizers to younger
women.
If psychiatrists are
treating younger
women of childbearing
(or before
childbearing) years
they should be better
versed in the drug
information using the
best medications
possible.

Johns
Hopkins Level
& Quality
Quality: good
Level: 3
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Källén, B., Borg,
N., & Reis, M.
(2013). The use
of central
nervous system
active drugs
during
pregnancy. Phar
maceuticals, 6(1
0), 1221–1286.
doi:10.3390/ph6
101221

To determine if
drugs that focus
on the central
nervous system
such as opioids,
anticonvulsants,
drugs used for
Parkinson’s
disease,
neuroleptics,
sedatives/
hypnotics,
antidepressants,
psychostimulant
s and a group of
other CNS active
drugs have an
adverse effect
on the fetus
when used
during early
pregnancy.

Data retrieved
from the
Swedish Medical
Birth Register
from 1996-2011

Nonexperimental
Qualitative
Meta-analysis

Literature review
used per each
medication mainly
the Swedish
Medical Register
regarding health,
pharmacology,
infant health, birth
rates, adverse
effects, birth
defects.

70,339/1,575,849
infants born had
congenital
malformation and
49,499 were severe
16,145 were
cardiovascular
11,157 were
ventricular septum or
atrial septum defect
and 4,552 had
hypospadias

More research
needs to be
completed of drug
use during
pregnancy. Not only
do medication
effect the fetus in
negative ways but
they also can
increase maternal
risk of GDM,
preterm labor,
stillbirths,
miscarriage,
preeclampsia,
placenta abruption,
hemorrhage, and
low Apgar’s each
case is different.
One must weigh the
benefits and risks of
each medication
during pregnancy.

1,552,382
women gave
birth, 42,881
reported use
purpose
medications
Non medicated
and medicated
women
compared.

Congenital
malformations per
drug
Opiods= 401/70,339
Anticonvulsants=
334/70,339
Anti-Parkinson’s=
78/70,339
Sedatives/hypnotics=
358/70,339
Antidepressants=
1,048/70,339
Psychostimulating =
more maternal
complications

Johns Hopkins
Level &
Quality
Quality: high
Level: 2
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Kulkarni, J.,
McCauley-Elsom,
K., Marston, N.,
Gilbert, H.,
Gurvich, C., de
Castella, A., &
Fitzgerald, P.
(2008).
Preliminary
findings from the
National Register
of Antipsychotic
Medication in
Pregnancy.
Australian & New
Zealand Journal Of
Psychiatry, 42(1),
38-44.
doi:10.1080/
0004867070
1732723

To outline the
establishment of,
and present
preliminary data
from, the National
Register of
Antipsychotic
Medication in
Pregnancy
(NRAMP

Australian
women,110
women with
schizophrenia,
there were a
total of 257
pregnancies,
resulting in
198 live births
The inclusion
criteria are
necessarily
broad because
the basic
question
pertains to the
relationship of
the
antipsychotic
medication to
maternal and
baby health
there is no
exclusion
criteria,

Non
randomized
Quantitative
Controlled

Information
regarding each
woman and her
infant is gathered
every 6 weeks
throughout her
pregnancy, at the
time of delivery,
and at 6 weeks, 12
weeks, 6 months
and 12 months after
delivery
Direct interview and
medical records,
and encompasses
personal history,
physical and mental
health of the
mother, psychiatric
management and
outcomes, and
pregnancy and
delivery details, as
well as health and
developmental
outcomes for the
infant

The establishment
of NRAMP, focusing
as it does on the
broader needs and
vulnerabilities of
pregnant women
requiring
antipsychotic
treatment, will
enable us to
develop guidelines
for their optimal
health-care
interventions.

Further
investigation to
guidelines followed
is needed.
Drastic changes in
medications for
schizophrenia or
other mental illness
may cause
decompensation
leading to relapse of
symptoms causing
more complications
for the patient’s
family dynamics.
Providers need to
be in contact with
each other before
such changes are
made. Medications
should never be
stopped cold turkey.
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Kulkarni, J.,
Worsley, R.,
Gilbert, H.,
Gavrilidis, E.,
Van Rheenen, T.
E., Wang, W.,
Fitzgerald, P.
(2014). A
Prospective
cohort study of
antipsychotic
medications in
pregnancy: the
first 147
pregnancies and
100 One year old
babies. PLOS
ONE, 9(5),
e94788.
doi:10.1371/jour
nal.pone.009478
8

To determine
the effects on
mother and child
of antipsychotic
use during
pregnancy

Data collected
from 205 to
2012 and a
finalized number
of 147
pregnancies
were followed
with142 live
births out of
these 100 babies
were followed
for one year
after birth

Nonexperimental
Qualitative

Information was
retrieved using the
Australian National
Register of
Antipsychotic
Medications in
Pregnancy
(NRAMP).
Baseline interview
involved social,
medical,
psychiatric,
medication and
obstetric history.
Women were
contacted every 68 weeks during
pregnancy and
asked questions
pertaining to
health. 6 weeks
after birth
depression and
neonatal health
were determined.
Then contacted
again at 12 weeks,
6 months and 12
months of infant
age.

Quetiapine and
Olanzapine were the
most commonly
prescribed

Overall
antipsychotic use
during pregnancy is
not warranted.
Congenital
abnormalities risk is
of a higher rate than
the general
population,
Maternal metabolic
effects are also
greatly increased
showing many
women to develop
GDM and maternal
decompensation of
psychiatric state
greatly increased
after delivery.
Mother-infant
bonding was less
likely to occur in
mothers on
antipsychotics.

53 women were
absent in antenatal
care
138 women had
gestational diabetes
Instrumental vaginal
delivery and
caesarean delivery
had higher rates in
user group.
18% of infants were
premature
37% had respiratory
distress at birth
43% had to be
admitted to NICU
Over 50% of mothers
were admitted to the
hospital within 12
months of delivery
for mental health
decompensation.

Some information is
unclear if it is
correlated with
medications or
mental illness.
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Louik, C., Lin, A.
E., Werler, M.
M., HernandezDiaz, S., &
Mitchell, A. A.
(2007). Firsttrimester use of
selective
serotoninreuptake
inhibitors and
the risk of birth
defects. New
England Journal
of Medicine,
356(26), 26752683.

To determine
the risk of birth
defects with
maternal use of
SSRI’s during the
first trimester of
the antepartum
period

Infants were
identified by
birth registries
and calling new
born nurseries
and labor and
delivery rooms.
Mothers were
interviewed in
person and by
phone after risk
was determine.

Non –
experimental
Qualitative

This study looked
at any birth defect
but did pay closer
attention to the
main groups that
SSRI’s have been
previously
associated with
such as
craniosynostosis,
omphalocele, and
congenital heart
defects.

Out of the 9849
infants with
malformations 127
had omphalcele 115
had craniosynostosis,
and 3724 had
congenital heart
defects (186
looping/laterality
defects, 620
conotruncal defects,
164 atrioventricular
defects, 363 right
ventricular outflow
tract obstruction
defects, 482 left
ventricular outflow
tract obstruction
defects, 1161 septal
defects, and 17 had
anomalous
pulmonary venous
return)

There is no
definitive
connection between
an increased risk of
birth defects and
SSRI use during
pregnancy.

9849 infants
with
malformation
and 5860 control
infants health
records were
used

st

1 trimester
exposure included
SSRI use from 28
days before the
LMP through the
th
4 lunar month
(112 days after the
LMP)

Even though
malformation were
found the overall
numbers were not
statically significant.

Each situation is
different and the
provider must
weigh the benefits v
the risk of both the
mother and fetus
before prescribing
new medications or
discontinuing
medications during
pregnancy.
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McCauley-Elsom,
K., Gurvich, C.,
Elsom, S., &
Kulkarni, J.
(2010).
Antipsychotics in
pregnancy.
Journal Of
Psychiatric &
Mental Health
Nursing, 17(2),
97-104. doi:10.
1111/j.13652850.
2009.01481.x

To presents
literature
surrounding the
use of
antipsychotic
medications in
pregnancy,
providing an
overview of the
historical and
contemporary
perspectives
which inﬂuence
clinicians
prescribing
practices
To summarizes the
literature relating
to the use of
antipsychotics in
pregnancy with a
focus on the most
commonly used
atypical
antipsychotics

Data were
sourced from
Medline,
CINAHL,
PsycINFo
Articles were
from 1967 to
2010.
Papers were
selected based
on the
abstracts

Qualitative
grounded
theory

The data was
measured by
medication
effects on the
fetus and or
neonate after
birth

This review identiﬁes
that the literature
provides no clear answer
for clinicians as to the
risk associated with the
use of antipsychotics in
pregnancy
Olanzapine had no
major malformations
but did have an
incidence with stillbirths,
and prematurity but the
highest incidence was
with spontaneous
abortions
Clozapine had no
conclusive evidence
Risperidone had adverse
events during pregnancy
and fetal anomalies
were moderate
Quetiapine had minimal
to no adverse effects
Aripirazole had high
rates of neural tube
defects resulting in
miscarriage.

Withholding
medications may be
more detrimental to
the mother then the
possible teratogenic
effect on the fetus.
Breast feeding is okay
with risperidone of
any kind
There are no
conclusive adverse
effects with other
types of antipsychotic
and breast feeding
Taking multiple
medications for
mental health
complications can
cause more
complications then if
they were to just use
one.
Balancing of both the
mental well-being of
the woman and the
safety of her baby
remains a complex
task for health
professionals.
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Peng, M., Gao, K.,
Ding, Y., Ou, J.,
Calabrese, J.,
Wu, R., & Zhao, J.
(2013). Effects of
prenatal exposure
to atypical
antipsychotics on
postnatal
development and
growth of infants:
a case-controlled,
prospective
study. Psycho
pharmacology,
228(4), 577-584.
doi:10.1007/s002
13-013-3060-6

To investigate the
developmental
effects of atypical
antipsychotics on
infants who were
born to mothers
taking an atypical
antipsychotic
throughout
pregnancy

76 infants
who
experienced
fetal exposure
to atypical
antipsychotics
was
compared to
that of 76
matched
control infants
who had no
fetal exposure
to any
antipsychotics

Non
Experimental
Case
Controlled
Qualitative

A newborn
assessment and
Apgar score at
birth and
followed up at 12
months of age.
Infant
development
included body
weight, height,
and neuro
behavioral
development
measurements at
2, 6, and 12
months of age.
evaluated by the
Bayley Scales of
Infant and
Toddler
Development

Fetal exposure to
atypical antipsychotics
causes short-term
delayed development
in cognitive, motor,
social–emotional, and
adaptive behavior still
by 12 months of age.
The mothers of the
exposed group had
higher rates of factors
known to increase the
risk for a negative
pregnancy.
a higher % of newborns
who were exposed to
antipsychotics met the
criteria for low birth
weight.

Antipsychotic
treatment should
continue during
pregnancy to
prevent relapse
although studies of
the effects of
antipsychotic
exposure during
pregnancy on
infants’
neurodevelopment
with longer follow
up period are
warranted.
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Petersen,
I., McCrea, R.
L., Osborn, D. J.
P., Evans,
S., Pinfold,
V., Cowen, P.
J., Gilbert, R., &
Nazareth, I.
(2014).
Discontinuation
of antipsychotic
medication in
pregnancy: A
cohort study.
Schizophrenia
Research,
159(1), 218-225.
doi:
http://dx.doi.org
/10.1016/j.schre
s.2014.07.034

To determine
the effects of
discontinuation
of antipsychotics
during
pregnancy

Overall 495,953
pregnancies of
365,138 women
were found. In
this 1442 of the
women had
ongoing
antipsychotic
use

Meta-analysis
Quantitative

Data was gathered
from The Health
Improvement
Network (THIN)
primary care
database from 578
practices which
covers the majority
of the UK’s
population.

207 women on
typical antipsychotics
before pregnancy
st
there was 1
trimester d/c
rd
134/207 and by 3
trimester 168/207

Providers need to
be mindful of
schizophrenia and
bipolar surfacing
around childbearing
ages.

Women were
identified from
1/1/95 to
12/31/12 for 6
month before
pregnancy and
then there after
that were on
antipsychotic
medications during
that time

279 on atypical
antipsychotics before
pregnancy there was
st
1 trimester d/c rate
rd
of 129/279 and by 3
trimester 172/279
Discontinuation rates
depended on
medication and
dosage. Women
prescribed in lower
doses were less likely
to d/c medications.

Trends still show a
strong link between
the discontinuation
of antipsychotic
medications and
pregnancy. Be this
from the psych
provider, primary
provide, OB/GYN
provider or by
independent
decision based
solely on the
pregnancy.
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Reis, M., &
Källén, B. (2013).
Combined use of
selective
serotonin
reuptake
inhibitors and
sedatives/
hypnotics during
pregnancy: risk
of relatively
severe
congenital
malformations
or cardiac
defects. A
register
study. BMJ
Open, 3(2),
e002166.
doi:10.1136/bmj
open-2012002166

To determine
the relation
between SSRI’s
benzodiazepines
and the adverse
effects the fetus.
Looking at both
severe
congenital
malformations
and or cardiac
defects.

A total of 10,511
infants that were
born to women
that used SSRI
medications only
1000 infants
whose mothers
used
benzodiazepines
only and 406
infants whose
mothers used a
combination of
benzodiazepines
and SSRI’s

Cohort – study
Meta-analysis
Quantitative

Information
retrieved from
Swedish Medical
Birth register for
women and
children that were
birthed from July
1995- December
2008.

(CM congenital
malformations, CVD
cardio defects)
SSRI = 12195
exposed; 396 CM and
121 CVD
SSRI w/o sedative/
hypnotic = 10,511
exposed; 337 CM and
103 CVD
Benzodiazepines
w/o SSRI = 1000
exposed; 37 CM and
13 CVD
HBRA w/o SSRI = 776
exposed; 22CM and 2
CVD
Other sedative
/hypnotics w/o SSRI
= 606 exposed; 21
CM and 5 CVD
SSRI w/ benzo’s =
822 exposed; 46 CM
and 13 CVD
SSRI w/HBRA= 309
exposed; 8 CM and 2
CVD
SSRI w/ sedative/
hypnotic = 256
exposed; 10 CM and
3 CVA

Further studies are
recommended
before ongoing use
during pregnancy.

No other CNS –
active drugs
were used in this
study

Midwifes
interviewed
patients at their
first antenatal visit
information was
put into
Anatomical,
Therapeutic,
Chemical
classiﬁcation
system for data
retrieval.
Congenital
malformation were
identified by the
medical birth
register, birth
defect register,
and patient
register.
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Risk of congenital
malformations
linked to
maternal use of
antipsychotics.
(2008). Brown
University Psycho
pharmacology
Update, 19(8), 17.

To determine the
effects on the
fetus of
antipsychotics
during pregnancy

Medical data
of infants born
to 2,908
women in
Sweden who
took
antipsychotics
or lithium
during early
pregnancy who
gave birth
between July
1995 and July
2005.

Qualitative
non
experimental
control

Mothers were
split into two
group’s 1
women who
took either
dixyrazine or
prochlorperazine
and 2 women
who took any
other
antipsychotic
during the first
trimester.

benefit of
pharmacological
treatment must
outweigh the
possible risks in a
short & long
perspective for both
the woman & the
fetus
Dixyrazine used by
2062 women
Prochlorperazine
used by 224 women
and Congenital
malformations were
low
Other antipsychotics
had significant risk
for congenital
malformation, with
increased odds when
excluding mild and
common
malformations
including an
increased risk of low
birth rate, preterm
births, and
intrauterine growth
retardation.

Risk-benefit analysis
concludes
antipsychotic use
during first
trimester poses a
moderate risk for
congenital
malformation, but
when clinically
indicated
antipsychotics
should not be
withheld during
pregnancy
Over all further
study is
recommended
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Ross, L. E.,
Grigoriadis, S.,
Mamisashvili, L.,
Vonder Porten,
E. H., Roerecke,
M., Rehm, J.,
Dennis, C.,
Koren, G.,
Steiner, M.,
Mousmanis, P.,
& Cheung, A.
(2013). Selected
pregnancy and
delivery
outcomes after
exposure to
antidepressants
medication.
JAMA Journal of
the American
Medical
Association
Psychiatry. 70(4)
:436-443.
doi:10.1001/jam
apsychiatry.2013
.684.

To determine if
maternal
antipsychotic
use during
pregnancy is
associated with
an increased risk
of adverse
pregnancy or
delivery
outcomes.

3074 citations
identified 735
articles were
reviewed in full
and 51 articles
reporting on
outcomes of
interest met the
meta-analysis
criteria.

Meta-analysis
Quantitative

Information was
reviewed from
Databases that
were searched.
Databases that
were searched
include MEDLINE,
PsychINFO,
EMBASE, and
scopus. Reference
lists and metaanalysis were
searched, studies
were considered if
they were
published in
English and had
original data.

Spontaneous
abortion is not
conclusive of
antidepressant use.

Antidepressants can
have significant
effects on fetal wellbeing.

Preterm delivery
defined as <37 weeks
showed a strong
association with
antidepressant use

Weighting the pros
and cons of
medications is
imperative when
deciding to continue
or discontinue
treatments.

Neonates small for
gestational age had a
strong association
with antidepressant
use
APGAR scores
showed a decrease in
neonates that were
exposed to
antidepressants in
utero.

More research and
investigation needs
to be completed on
each drug class to
determine the
overall outcomes
for both mom and
baby.
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Sadowski, A.,
Todorow, M.,
Yazdani Brojeni,
P., Koren, G., &
Nulman, I.
(2013).
Pregnancy
outcomes
following
maternal
exposure to
secondgeneration
antipsychotics
given with other
psychotropic
drugs: a cohort
study. BMJ
Open, 3(7),
e003062.
doi:10.1136/bmj
open-2013003062

To examine
reproductive
safety of second
generation
antipsychotics
and to compare
pregnancy
outcomes
between second
generation
mono and
polytherapy with
psychotropic
medications

133 women
using second
generation
antipsychotic
(SGA)
medications (37
monotherapy
and 96
polytherapy) and
133 healthy non
medicated
women (control
group)

Qualitative
Experimental
Control

Participants
identified by a
database from the
motherisk program
at the hospital for
sick children from
2005-2009.
Mothers that used
SGA medications
for 4 or more
weeks during
pregnancy were
invited into the
study

Exposed group had
more C-section
deliveries, higher
preterm deliveries,
LGA, and higher NICU
presenting with poor
neonatal adaptions
signs: central
nervous system,
respiratory and
gastrointestinal
problems.

Polytherapy SGA
poses more harm to
the mother and
fetus then
monotherapy.

266 women total

Comparison group
= healthy normal
women and
pregnancies from
the same database
Telephone
interviewing 20092012 of both
groups regarding
children’s health
and Medical chart
review of children
at primary clinics

Polytherapy vs
monotherapy Poly =
shorter gestational
age, and major
malformations.
Higher admission to
NICU for poor
neonatal adaption
signs also noted
Exposed women pre
pregnancy were
heavier, smokers,
breast fed less, less
likely to take prenatal
vitamins and had
more comorbidities.

Polytherapy should
be seriously
considers and taken
into perspective in
each individual case
looking at the real
risks and benefits
for the mother and
baby.
Reproductive safety
of polytherapy of
antipsychotic
medications needs
to be studied more
with a greater
population size
while taking into
consideration the
reality of
comorbidities,
genetic and
environmental
factors of the
mother.
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Toh, S., Li, Q.,
Cheetham, T.,
Cooper, W., Davis,
R., Dublin, S., & ...
Andrade, S. (2013).
Prevalence and
trends in the use of
antipsychotic
medications during
pregnancy in the
U.S., 2001-2007: a
population-based
study of 585,615
deliveries. Archives
Of Women's Mental
Health, 16(2), 149157.
doi:10.1007/s00
737-013-0330-6

estimate the
prevalence of and
temporal trends
in prenatal
antipsychotic
medication use
within a cohort of
pregnant women
in the U.S

Women ages
15-45 that
gave birth
between
2001-2007 in
11 US health
plans totally
585,615
deliveries
4771 where to
women on
atypical
antipsychotics
at some time
throughout
pregnancy

Quantitative
Grounded
theory

Used data from
the Medication
Exposure in
Pregnancy Risk
Evaluation
Program and the
11 health plans affiliated
research
institution
identifying when
the
antipsychotic
was used and
for how long it
was used to
determine
frequency and
symptoms of
the medications
for
schizophrenia
bipolar disorder
or depression
any time from
180 days before
pregnancy
through delivery

Prevalence of
antipsychotic was
highest at 0.5%
during the first
trimester decreasing
to 0.3 % in the
second trimester and
0.2% in the third
trimester.
2.5-fold increase in
the prevalence of
prenatal use of
atypical
antipsychotics
81 % of the deliveries
to women with
atypical antipsychotic
exposure any time
from 60 days before
pregnancy through
delivery had a
recorded diagnosis of
depression, bipolar
disorder, or
schizophrenia.

Treating psychiatric
conditions during
pregnancy is
generally
recommended
MD must weigh the
benefits and risks of
any medication use
during pregnancy
and possible
adverse effects to
the fetus and or
mother.
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Vigod, S. N.,
Gomes, T.,
Wilton, A. S.,
Taylor, V. H., &
Ray, J. G. (2015).
Antipsychotic
drug use in
pregnancy: high
dimensional,
propensity
matched,
population
based cohort
study. BMJ :
British Medical
Journal, 350,
h2298.
doi:10.1136/bmj
.h2298

To understand
both maternal
and perinatal
effects/outcome
s associated with
maternal
antipsychotic
(quetiapine,
olanzapine,
risperidone)
drug use in
pregnancy

1021 women of
any age/race
that had
delivered 1 child,
between the
years of 2032012 in Toronto,
Ontario.
Mothers had to
be on two or
more
antipsychotic
medications
during the first
and second
trimesters of
their pregnancy
and 1021 non
medicated
healthy mothers
(control group)

Experimental
Control

Health records of
mother and baby
were reviewed via
ICES’ MOMBABY
datafile, Canadian
Institutes of Health
Information
Discharge Abstract
Database, ICD-10CA codes, Ontario
Mental Health
Reporting System,
Registered Persons
Database, National
Ambulatory
Reporting System,
Ontario Health
Insurance Plan.

Antipsychotic use
during pregnancy
showed higher rates
of gestational
diabetes,
hypertensive
disorders of
pregnancy, preterm
birth, placental
abruption,
macrosomia,
induction of labor,
caesarean sections,
operative vaginal
delivery, and
readmission to the
hospital.

Must weight risks
and benefits of
antipsychotic use
during pregnancy

2042 women
total

Infants showed
higher rates of
preterm birth,
intraventricular
hemorrhage,
seizures, sepsis, and
neonatal adaptation
syndrome.

Women that use
antipsychotic
medications during
pregnancy put
themselves, their
pregnancy and child
at higher risk for
complications.
Overall
antipsychotic
medications are not
to be discontinued
during pregnancy if
maternal mental
health warrants
them.
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Wichman, C. L.
(2009). Atypical
antipsychotic use
in pregnancy: A
retrospective
review. Archives
Of Women's
Mental
Health, 12(1), 5357.
doi:10.1007/s00
737-008-0044-3

determine the
prevalence of use
of atypical
antipsychotics in
pregnancy and
describe infant
outcomes
associated with
these exposure

Retrospective
chart review of
all pregnant
women
presenting at
our medical
center, from
the years 1993
to 2007. Of the
30,092 delivers
16 mothers
were on
atypical
antipsychotics

Controlled
Experimental

The obstetrical
database listed all
medications
taken during
pregnancy then
confirmed by
individual chart
review.
Infant outcomes
were assessed by
gestational age,
birth weight,
Apgar scores,
NICU admission,
congenital
malformation or
ongoing medical
issues, and
medical charts
were reviewed
from birth to Dec
31th 2007.

5/16 infants were
female
3/16 male infants
were premature
Average APGAR score
at 1 min was 6.9 and
at 5 min was 8.2
4/16 infants required
NICU admission after
delivery.
6/16 infants showed 0
malformations,
neurobehavioral
difficulties, or feeding
difficulties
1/16 infants had a
major malformation
3/16 had heart
murmurs that
disappeared in 1 year
2/16 had behavioral
concerns that initiated
after age 3 years.
1/16 infants died at 5
weeks of age with an
autopsy revealing
positional asphyxia.

Populations group
was small, further
investigation needs
to be done.
Antipsychotics are
not recommended
to be stopped with
pregnancy.
Antipsychotic
medication should
be considered highrisk and both
mother and fetus
should be
monitored
appropriately
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Summary
It is difficult to effectively distinguish an appropriate maternal and neonatal balance when
assessing the continuation or discontinuation of maternal antipsychotic, mood stabilizer, and or
antidepressant medication use during pregnancy. This difficulty is due to clinical and moral
obstacles that can arise. One obstacle is that mothers do not want to be a part of a research
project during pregnancy when outcomes are unknown and possible lethal or gross adverse fetal
effects may occur. Medical providers are taught that if medications are known to cross the
placental barrier they should be avoided during pregnancy. However they do not always assess
the effects of discontinuation on the mother’s wellbeing.
The critical review of the literature shows that there is still much need for more in-depth
research studies to be conducted in order to accurately determine the safety of continuing and/or
discontinuing antipsychotic, mood stabilizing and/or antidepressant medications. Chapter four
will give a final conclusion of the critical review by answering the practice question, identifying
trends and gaps in the literature, implications for nurse-midwifery practice, and
recommendations for practice in the future, integration and application of the theoretical
framework and give a complete conclusion of all the information gathered.
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Chapter IV: Discussion and Conclusion
This chapter will discuss the critical review of the literature. This discussion will review
the literature synthesis, current trends and gaps in the literature, implications for nurse-midwifery
practice, recommendation for future research and finally integration and applications of the
theoretical framework. This chapter will cover the information that was presented in the matrices
in chapter three. The purpose for this critical review is to understand if antipsychotics, mood
stabilizers, and antidepressants should be continued or discontinued during pregnancy or if they
negatively impact the fetus/neonate development, maternal wellbeing, and/or maternal-fetal
interactions. Nurse-midwives need to understand the importance of continuing or discontinuing
these medications in pregnant patients. Having a good understanding of appropriate medication
use in pregnancy and the potential effects on the mother and baby are very important to having a
happy, healthy patient outcome.
Literature Synthesis
This critical review of the literature was completed to attempt to determine if
antipsychotics, mood stabilizers, and antidepressants should be continued or discontinued during
pregnancy or if they negatively impact the fetus/neonate development, maternal wellbeing,
and/or maternal-fetal interactions, with the main focus of maternal/fetal outcomes with
continuation or discontinuation of medications in pregnancy at any time. The purpose of this
review was to evaluate the safety of these medications for maternal wellbeing and fetal
outcomes. This synthesis will be continued in the recommendations paragraphs to follow.
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Current Trends
Current trends in the literature discussed maternal and fetal wellbeing in regards to
continuation or discontinuation of antidepressants, antipsychotics, and or mood stabilizing
medications. To adequately answer the review purpose many factors must be considered.
Providers must educate their patients with current information and make the best decisions
possible in order to keep the mother mentally stable and the fetus physically and mentally viable
and healthy.
It is important to understand how much progression healthcare has made over the years in
regards to mental health medications and pregnancy. It is beneficial to understand history and
progress when understanding why current trends are important. In the 1970’s, antipsychotics
were considered not only safe during pregnancy, but beneficial to offspring (Clues to preventing
schizophrenia, 1979). In lab rats, the pups were determined to have less dopamine in their brains
upon birth making them less susceptible to schizophrenia (Clues to preventing schizophrenia,
1979). This decreased risk of schizophrenia was the only fetal benefit for neuroleptic or
antipsychotic medication use during pregnancy, and there were no negative impacts noted.
Antidepressants in pregnancy have been used for decades. Many studies were completed
and most were in agreement that antidepressants such as SSRI’s were deemed safe across all
trimesters in pregnancy (Musa & Smith, 1979). However, tricyclic antidepressants have been
linked to negative effects in the infant, such as drug withdrawal, malformation, neonatal
morbidity, and hypothermia, making these medications a bad choice in pregnancy (Musa &
Smith, 1979). The Musa & Smith study from 1979 showed that interest in maternal fetal safely
was growing and better outcomes for both mom and baby were warranted.
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Current literature supports the need for positive maternal/fetal outcomes. Literature
suggests that medications during pregnancy can cause fetal harm; however, discontinuation of
medications during pregnancy can cause significant maternal mental decompensation
(McCauley-Elsom, Gurvich, Elsom, & Kulkarni, 2010). Finding the best treatment plan is the
ultimate goal when providing care for pregnant mothers with mental health disorders. Studying
pregnant women for medication use and fetal safety is difficult. Many women do not want to
volunteer to participate in research related to the health of their unborn child. Current trends
show research from large data bases from different countries or large hospital systems
(Evidence-based review assesses safety of antipsychotics during pregnancy, 2009). Research
looking at data bases with maternal consent shows maternal medication compliance and maternal
outcome as well as fetal outcomes. This helps show the rates of adverse fetal effects with various
medications and each maternal psychiatric diagnosis. It is important to note that maternal
diagnosis and social economic behaviors/status were not taken into consideration during this
critical review.
Gaps in the Literature
Several gaps exist in the literature. A significant research limitation is the sole focus on
medication continuation or discontinuation and maternal/ fetal/ neonatal effects. Co-morbidities,
medical diagnosis, psychological diagnosis and socio-economic status were not assessed or taken
into consideration which may skew results. Issues such as maternal diabetes, illegal drug use,
and tobacco use could impact the fetal/neonatal outcomes when medications were continued or
discontinued during pregnancy.
Other gaps in the literature include the reliance on data from large databases. Data
retrieval such as this can be difficult to determine to be completely accurate. Data retrieval from
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large databases does not take anything into consideration except for numbers and outcomes. This
source does not look at specifics in people and populations but more as numbers and outcomes.
Another large gap in the literature is the psychiatrist, primary care provider’s, and midwife’s
knowledge regarding medication safety in pregnancy and psychiatric disorders. “Decisions
regarding the best form of treatment are complicated when there is a requirement to medicate
women who are acutely psychotic in pregnancy” (McCauley-Elsom & et al., 2010. p.101). This
challenge highlights the central purpose of this review regarding balancing maternal health with
potential risks to the infant.
Implications for Nurse-Midwifery Practice
This critical review of the literature has a vast array of implications for the nurse midwife
practice. Understanding the risks and benefits to both patients (maternal and fetal) when looking
at their medication regime is key to outstanding practice. When determining if medications need
to be discontinued or continued throughout pregnancy, the midwife needs to be able to provide
pertinent information for both the patient and possibly the prescribing physician. Provider
education is of utmost importance, but also an understanding of the midwifery scope. When is it
appropriate for the midwife to take over psychiatric medication dosing during pregnancy and
when would this become an inappropriate use of practice? Who should prescribe medication
during pregnancy? Midwifery scope of practice does not usually include extensive psychiatric
medications, but mental health patients benefit from midwifery cares (American College of
Nurse-Midwifes, 2015). Midwives need to understand psychiatric medications effects, side
effects, and potential harmful effects to both the mother and developing fetus to help protect
women and ensure they get the care they deserve.
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Knowing that the potential effects of medications on fetal development and maternal
wellbeing is of greatest importance, midwives are advocates and leaders in best practices for
women’s health and fetal wellbeing. The decision to continue or discontinue medications needs
to be driven by more than just fear of medication use in pregnancy. There needs to be supported
and well documented research and information before decision of discontinuation or
continuation of medications is applied. It is well known that discontinuation of antipsychotics
can lead to a relapse of symptoms and mental health decompensation leading to “personal
suffering and increased family and societal burden” (Peng & et al., 2013, p. 578). However, all
psychotropic medications cross the placenta, thus exposing the fetus to the effects of the
medications (Peng & et al., 2013).
It is important for midwives to understand that the psychiatrist may not have taken this
patient’s child bearing needs into consideration while prescribing medications. Many studies
have shown that psychiatric providers focus more on the maternal side in managing symptoms,
and focus less on the fetal realm of healthcare (Peterson et al, 2014). Studies on psychiatrists
have shown that many do not discuss reproductive issues with patients, including contraceptive,
pregnancy, and potential complications (James, Paton, Lelliott, Barnes, & Taylor 2009). The
reality of this is that providers are prescribing young women medications but not fully educating
them on life choices or safe sex practices. Midwives have the ability to see women of all ages
and educate women at a young age, before life changing events occur. If mental instability
occurs throughout a woman’s life, education is needed prior to and during pregnancy to help
women understand the risks associated with medications crossing the placenta barrier
Midwives need to understand that depression in pregnancy and postpartum is common.
In fact, up to 20 percent of women without mental health complications develop depression
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during pregnancy or within the first year postpartum (Midris, 2014). Women need to be educated
and treated for mental health issues before, during, and after pregnancy (Midris, 2014). It is not
only the psychiatric provider’s role to treat women before pregnancy but also the midwives’ role
as well. Women in childbearing ages need education on medications, mental stability, and the
risks a pregnancy could bestow upon them (Midris, 2014). Women need to understand that
discontinuing an antidepressant, antipsychotic, or mood stabilizing medication could cause a
depressive, manic, or psychotic relapse and truly impact them negatively during pregnancy or
after delivery in the postpartum stage. This relapse could greatly impact the mother’s ability to
care for herself and her family and has the potential to cause a postpartum psychosis episode
(Cohen et al., 2006). Midwives need to educate patients, physicians, and themselves about
antidepressant, antipsychotic and mood stabilizing medication use in pregnancy in order to safely
and effectively treat patients and obtain positive outcomes.
Recommendations
Recommendations for the research questions: to determine if antipsychotics, mood
stabilizers, and antidepressants should be continued or discontinued during pregnancy or if they
negatively impact the fetus/neonate development, maternal wellbeing, and/or maternal-fetal
interactions; was divided into three main categories with the research assessed in the matrices
above. Recommendations for all three medication family groups were divided equally into sub
categories of continuation/discontinuation, provider education, and need for more research for
recommendation.
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Continuation vs discontinuation.
When discussing pregnant women, one is discussing the treatment of not only one
patient, but two. Balancing the safety of the mother’s mental health with the physical and mental
health of the developing fetus is pertinent to appropriate care. Continuation of medication use
during pregnancy needs to take many factors into consideration, maternal mental stability, fetal
effects of continuation, trimester of use, and maternal/fetal effects of discontinuation need to be
addressed and prioritized. Antipsychotics, antidepressants, and mood stabilizing medications can
have negative adverse effects on the developing fetus at any stage of pregnancy, but
discontinuation of medication can impact the mother and still cause negative impacts on the
developing fetus. It is important to note that fetal/neonatal effects can not only be linked to
medication use but also to maternal mental illness (Kulkarni et al., 2014). This factor should be
of highest consideration when determining appropriate treatment during pregnancy.
Where should priority lie, with the patient before the midwife or the patient that is
growing inside? Balancing maternal well-being with safety of the developing fetus soon to be
neonate is a complex and trying task for healthcare professionals (McCauley-Elson, Gurvich,
Elsom & Kulkarni, 2010). Discontinuation of medications can be more detrimental to the mother
than continuation of medications and the teratogenic effects that can occur to the developing
fetus (McCauley-Elson, Gurvich, Elsom & Kulkarni, 2010). Antipsychotics, antidepressants,
and mood stabilizing medications have all been linked to adverse effects on the developing fetus
no matter the time frame of maternal use, whereas discontinuation has been strongly linked to
maternal decompensation and adverse fetal effects. Overall therapeutic medication monitoring
and careful planning are recommend with continuation of medications for mothers with severe
mental health disorders (Galbally, Snellen, Walker, & Permezel, 2010). Increasing fetal
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surveillance, maintaining maternal sleep patterns, and promoting maternal mood stability with
increase prenatal visits are helpful for effective medication dosing and fetal and maternal safety
during pregnancy (Galbally, Snellen, Walker & Permezel, 2010). After delivery, maternal and
fetal bonding needs to be closely monitored and active interventions are mandatory. Postnatally
the infant needs to be assessed for medication withdrawal, toxicity, and sedation (Balbally,
Roberts & Buist, 2010). Overall neonatal monitoring needs to occur as if the infant presented as
high risk. The neonate needs to be closely monitored for neurodevelopmental complications for
the first two years of life as adverse effects may not present until typical milestones are missed
(Peng et al., 2013). Antipsychotic, antidepressant, and mood stabilizing medications need to be
assessed as high risk for both maternal and fetal measures no matter how common the use of
these medications become (Wichman, 2009). If medications are going to be prescribed more
frequently, providers need to understand their potential for adverse effects when continued or
discontinued, and closer monitoring needs to be implemented.
Provider education.
Providers need to be aware of the current trends in medication prescribing, and all
providers that come into contact with childbearing women need to be able to provide education
about safe pregnancy. Ideally providers need to understand mental illness and its development in
women during childbearing ages. Schizophrenia, bipolar, and other mood disorders typically
developing in a person’s 20’s (Petersen et al., 2014), a direct correlation to the social time frame
for when women typically start families and have children. Education for preconception and
family planning during this time is fragile and lacking in healthcare. Many women do not
experience mental illness symptoms until pregnancy has occurred. Others don’t have
complications until the postpartum phase. This leaves mothers to believe this is normal in
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pregnancy and they stay un-medicated and still show adverse effects with fetal development,
maternal bonding and ultimately family development. These effects are due to mental illness and
can greatly impact family relationships and infant needs.
For women that are medicated before pregnancy, there is a provider trend to discontinue
medications out of fear of pregnancy, liability, and fetal harm (Petersen et al., 2014). No regard
is given to the mother’s mental stability if un-medicated. Providers need to be educated and feel
safe when leaving mothers on medications for mental illness to provide effective care. Liability
should not drive safety. Providers need more education but where are they to turn when in many
cases studies report that for best outcomes more research is needed.
More research required.
How are providers going to be informed with many studies show a need for more
research and patients aren’t willing to be the guinea pig? Antidepressants are so commonly used
in pregnancy, especially antidepressants in the SSRI family. However these medications have not
been determined safe for fetal development during pregnancy (Ross et al., 2013). SSRI’s have
been shown to have significant negative fetal effects while used in pregnancy such as
spontaneous abortion, preterm delivery, small for gestational age, low APGAR scores and flat
affect (Ross & et al., 2013). Yet these medications are classified as safe for use during pregnancy
making them the most commonly used mental health medication is pregnancy (Cohen et al.,
2006). Overall more research is needed to determine if the adverse effects on the developing
fetus are related to medications, maternal socioeconomic barriers, mental illness or all factors put
together (Reis & Kallen, 2013). When looking at antidepressants the provider needs to also
assess the situation. Yes SSRI’s are a category B but they also show adverse effects to fetal
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development. The degree of harm done if medications were continued vs if they were
discontinued needs to be assessed and researched (Louik et al., 2007).
When looking at research for antipsychotic medication use in pregnancy there is much
debate and more research is needed to make the murky water clear for providers. It may be
beneficial to divided research into groups by maternal adverse effects when assessing safety in
pregnancy. All in all pregnancy is not the time to experiment but if maternal use is already
occurring medication effectiveness vs metabolic syndromes caused by medications should be
taken into consideration with future studies (Boden et al., 2012). Patients that are using
antipsychotic medications prior to pregnancy typically have co-morbidities that also need to be
evaluated with research. Research focuses on medications and pregnancy but not other factors
such as promiscuity, illegal drug use or behaviors, socioeconomic status, obesity, relationship
status or other causative factors for poor outcomes (Gentile, 2010). Research needs to be finer
turned to special consideration and separation of medications; maternal and fetal effects are just
one factor (Hanley & Mintzes, 2014). Conclusively when looking at antipsychotics as a whole
more research is needed with greater population size and the reality of co-morbidities, genetics,
environmental factors and maternal situation bases to effectively give appropriate
recommendations for antipsychotic use in pregnancy (Sadowski et al., 2013).
Mood stabilizing medications is a large category that needs to be separated into small
categories. Ultimately medication use should be discussed prior to pregnancy (Galbally, Roberts,
& Buist, 2010). Medications should not be used if a woman is actively trying to get pregnant but
after pregnancy occurs medications may or may not be discontinued. It is a difficult line for
providers to walk. Just as in the case of antidepressants and antipsychotics more research is
needed to help providers make the best informed decision. Providers need to actively weigh the
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risks, alternatives, and benefits to medications continuation or discontinuation with the limited
research provided (Kallen, Borg, & Reis, 2013) while including women in the decision making
process. More research is required to be able to safely take care of both patients during
pregnancy when looking at continuation or discontinuation of maternal medications for mental
health purposes. There is not enough research to adequately guide providers to educate patients
effectively when looking at adverse fetal or maternal side effects. Medications, situations, and
current research needs to be weighed to make the best patient outcome. Overall more research is
required for mental health medications and pregnancy.
Application of Theoretical Framework
The theory chosen for this critical review of the literature was Jean Watson’s theory of
Human Caring/Caring Science. This theory has been implemented throughout in the discussion
of provider and patient education and understanding of medication continuation or
discontinuation during pregnancy. Jean Watson’s theory of caring ultimately breaks down to the
more antenatal care a woman receives in pregnancy the better the outcome of the fetus and
maternal/neonatal bonding. This theory is set in the bases of love, compassion towards others
and positive morals (Wagner, 2010).
The theory of Human Caring/Caring Sciences is specific to the recommendation for
provider education and the need for research. Midwives need to be able to have the education to
be able to balance the well-being of both the mother and the developing fetus to ensure the best
outcome for both (McCauley-Elsom, Gurvinch, Elsom & Kulkarni, 2010). Midwives are
bestowed with the ability to look at patients as patients not a disorder and to look at pregnancy as
normal not a complications. This alone shows that midwives are more apt to practicing the
theory of Human Caring/Caring Sciences over any other. Patients are at the forefront of
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midwifery cares not the present illness or reason for their visit. This is important when looking at
medication use in pregnancy.
In Jean Watson’s Theory of Human Caring/Caring Science (Wagner, 2010), there are
seven main components that truly define midwifery practice. Each of the components applies to
midwifery practice and the decision to continue or discontinue medication. The first component
is moral commitment to protect and enhance human dignity. Midwives show this by including
women in care planning and in decision making. Also this is shown by the ultimate goal of
protecting and serving others. The second component is respect/love for the person. This is the
definition of midwifery care. Midwives care about people, and treat them as such. Listening to
women under their care and planning treatment mutually shows respect for the individual patient.
The third component is caring consciousness of the situation. This is shown by the knowledge
that midwives have in regards to medications safety vs adverse effects for the mom and fetus.
Midwives educate the women in their care about the adverse effects of medications and help
them to weigh an exacerbation of symptoms with the risks associated with continuing
medications. The fourth component is heart centered care of mind body and spirit. This is again
shown by the midwifery care model. Midwifery care is not treating a diagnosis but instead
treating a patient who happens to need treatment. Midwives have the special ability to care for
the whole patient and educate them with the most up to date research so that they can make the
best decisions about their healthcare and future. The fifth component is inner harmony, the sixth
is caring conscious intention, and the seventh is authentic presence. These components are
shown in midwifery care by the midwives’ ongoing ability to not only listen to a patient but also
given them the time and encouragement when making decision about their care. Midwives aren’t
grouping every patient with the same diagnosis the same way. Midwives treat each patient as an
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individual and help that patient make the best decision that pertains to their specific situation.
When midwives are given the ability to be a part of a patient’s care they give that patient the best
individualized care plan that helps them make the best decisions about their care. When looking
at medications for mental health complications in pregnancy, the midwife has the ability to
educate the mother and themselves on the risks, benefits and alternatives to continuing or
discontinuing their medications. These concepts define midwifery practice when comparing
them to the midwifery scope of practice. The midwifery scope of practice not only defines the
roles of a midwife but also the caring and art of compassion that midwives uphold daily.
“Midwives are uniquely placed to help ensure women receive high quality individualized care at
a distressing time” (Lyus, Creed, Fisher, & McKeon, 2014. p. 336) or at any time when they are
caring for women and newborns.
Mental health medications such as antidepressants, antipsychotics, and mood stabilizers
are going to be used in pregnancy. Treatment and patient care needs to be considered from all
angles and most importantly the mother’s ability to take care of herself in pregnancy and then her
ability to interact with her newborn after delivery vs the potential adverse fetal affects that could
arise during medications use in pregnancy (Evidence-based review assesses safety of
antipsychotics during pregnancy, 2009). The fear of liability needs to be minimized and the
compassion for maternal and fetal well-being needs to be maximized. This is where the
midwifery model of healthcare flourishes.
The midwifery philosophy of care is to “affirm the power and strength of women and the
importance of their health in the well-being of families, communities and nations. We believe in
the basic human rights of all persons, recognizing that women often incur an undue burden of
risk when these rights are violated” (ACNM, 2016, paragraph 1). This plays a direct role with
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Jean Watson’s theory of Human Caring/Caring Sciences. Midwives are a key member in the
independence of women and in the protection of their rights. In order for women to be
independent in healthcare they need a healthy knowledge base that focuses on their well-being.
Midwives are that caring informational source that woman can trust and with whom they can feel
safe. Midwifery hold a role like no other in caring for women so that women can care for
themselves.
Conclusion
Each and every patient is different. Each and every patient has their own thoughts,
feelings, dreams, ambitions, motivating factors and disorders. Midwives understand this; thus
making an individualized healthcare plan for each patient is of the utmost importance when
implementing patient cares. It is not fully understood if medications such as antidepressants,
antipsychotics, and mood stabilizers should be discontinued or continued during pregnancy. It is
understood that maternal and fetal well-being is of the most importance when attempting to
decide what steps should be taken before and after pregnancy has been confirmed. Midwives
need to be aware that psychiatric providers may have not taken situational factors into
consideration, such as, the woman being treated is of childbearing age (Petersen et al., 2014).
This may fall into the hands of the midwife and this education of planning pregnancy over
accidental pregnancy should be implemented with every woman no matter her potential mental
health disorder.
Midwives need to be able to have the conversation with the patient to inform them of all
the risks, benefits, and alternatives to continuation or discontinuation of mental health
medications during pregnancy. Patients need to know that continuing medications can cause
adverse fetal effects as well as adverse maternal effect but will keep the patient mentally stable

MENTAL HEALTH MEDICATION IN PREGNANCY: CONTINUE OR DISCONTINUE

65

and she will be able to care for herself and her family, while discontinuation of the medications
may cause mental health relapse and potential hospitalization while still causing adverse fetal
effects related to mental illness (Boden et al., 2012). Midwives and patients need to
collaboratively make the best decision for the best possible outcome for both the patient and her
unborn child.
Understanding that fear should not drive decision making is the midwife’s role. Knowing
how to monitor patients at a therapeutic medication level, ensuring mothers have proper dietary
and water intake along with a healthy sleep pattern is important for pregnancy and best outcomes
for all (Galbally, Snellen, Walker & Permezel, 2010). Truly this is the foundation of midwifery
care in pregnancy for all women, not just women on high risk medications during pregnancy.
Discharge planning should follow suit as well. While midwives educate all mothers on self-care,
fetal monitoring, safe environment, postpartum depression and routine follow up visits, special
consideration must be taken for mothers with a diagnosed mental health disorder. Regardless of
medication use in pregnancy, the postpartum period places all women in a fragile state; adding
mental illness to the equation heightens the fragility and puts mothers more at risk. Mothers will
need midwifery support, extra visits and additional supportive relationships to ensure maternal
neonatal bonding and to reinforce the maternal/infant relationship (Galbally, Snellen, Walker &
Permezel, 2010).
It is important for women to feel safe when receiving healthcare. Leaving them out of
important decisions in their health care will make them become less responsive and less
compliant. Midwives have the ability to bond with women on a personal level thus creating trust
within the healthcare system leading to compliance and positive outcomes. To determine if
antidepressants, antipsychotics, and mood stabilizing medications be continued or discontinued
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in pregnancy is situational and in the hands of the provider/midwife and the patient. More
research may be needed to be able to give a definitive yes or no but for now the importance of
education for child bearing women prior to pregnancy as well as newly pregnant women is the
foundation for the greatest outcome both for the mother and the developing fetus/neonate.
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